GenSight Biologics S A : AGM 2024 – Board nominees

GENSIGHT BIOLOGICS

A French Société Anonyme (corporation)

with share capital of €1.959.268,10

74 rue du Faubourg Saint Antoine

75012 Paris

751 164 757 - Paris Trade and Companies Registry

NOMINATION OF Laurence RODRIGUEZ AS DIRECTOR, GENERAL MEETING OF May 29,

2024

USUAL NAME: Laurence RODRIGUEZ

PERSONAL HOME ADDRESS: 43 rue Villeneuve 92110 Clichy (France)

DATE OF BIRTH: 02/09/1967

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Laurence Rodriguez has over 30 years' experience in the life sciences industry, including 13 years in the rare diseases business at Sanofi Genzyme, where she held a range of executive roles. As Head of the Rare Diseases & Rare Blood Disorders unit at Sanofi Genzyme, she oversaw the successful launch of various rare disease products developed or acquired by the Company. She joined GenSight Biologics in May 2021 as Head of Operations for France. She handled the early access program in preparation for LUMEVOQ®'s commercialization and created strong and trustworthy relationships with the various stakeholders.

Laurence Rodriguez holds a bachelor's degree in nutrition and Biochemistry and a master's degree from Sciences Po, Paris, France, and completed an Organization Leadership Program at the Harvard Business School.

OFFICES IN THE COMPANY: Chief Executive Officer, non-independent

NUMBER OF SHARES OF THE CORPORATION OWNED: 0

GENSIGHT BIOLOGICS

A French Société Anonyme (corporation)

with share capital of €1.959.268,10

74 rue du Faubourg Saint Antoine

75012 Paris

751 164 757 - Paris Trade and Companies Registry

NOMINATION OF William J. MONTEITH AS DIRECTOR, GENERAL MEETING OF May 29,

2024

USUAL NAME: William J. MONTEITH

PERSONAL HOME ADDRESS: 6852 Williams Place Sims, North Carolina, USA, 27880

DATE AND PLACE OF BIRTH: June 5th, 1957

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Mr. Monteith has over 43 years of experience in both small molecule and large molecule pharmaceutical manufacturing. During his career, he has held increasing positions of responsibility for Operations, Quality and Technical Support. He has been directly involved in the site search, design and build out of 6 pharmaceutical and biotech facilities. While at Wyeth and Sandoz he oversaw the successful implementation of remediation activities for regulatory actions. He was the General Manager for Dendreon when the approval and commercialization of the first dendritic cell , personalized medicine was launched. He later became the Executive Vice President of Dendreon responsible for the manufacturing Supply Chain and the launch of Provenge in Europe. After the sale of Dendreon to Valeant, he was appointed the Chief Operating Officer at Progenitor Cell Therapy, a CDMO that was eventually acquired by Hitachi Chemical. During his role with Hitachi, he oversaw the expansion of their Allendale NJ facility as well as the buildout of a cell and gene therapy facility in Yokohama Japan. Upon leaving Hitachi Chemical Advanced Therapies, Bill joined Cellectis as the Vice President Manufacturing, North America were he was responsible for locating a CarT manufacturing facility in North America, eventually overseeing the purchase and build out of a facility in Raleigh, North Carolina. Shortly after the buildout, Bill was appointed the Executive Vice President of Global Operations for Cellectis responsible for operational departments in both Raleigh and Paris. Upon leaving Cellectis, Bill was named Chief Operating Officer for Stridebio, a research development company focused on AAV products for rare disease. There he was responsible for the buildout of the operations departments and a clinical manufacturing facility. Since his retirement, Bill has taken the role of Program Director for the North Carolina Life Sciences Biomanufacturing Forum which is a trade organization that advocates for the life sciences companies which operate in the state.

OFFICES IN THE COMPANY: Independent director

NUMBER OF SHARES OF THE CORPORATION OWNED: 0

GENSIGHT BIOLOGICS

A French Société Anonyme (corporation)

with share capital of €1.959.268,10

74 rue du Faubourg Saint Antoine

75012 Paris

751 164 757 - Paris Trade and Companies Registry

RENEWAL OF THE DIRECTOR'S MANDATE OF MR. MICHAEL WYZGA, GENERAL

MEETING OF May 29, 2024

USUAL NAME: Michael WYZGA

PERSONAL HOME ADDRESS: 80 Beacon Street, Apt 4, Boston MA 02108, USA

DATE AND PLACE OF BIRTH: 03/11/1955 in Rhode Island, USA

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Michael Wyzga served as a director of OncoMed from October 2013 until the closing of the Merger. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is a member of the boards of directors of Adagio Therapeutics and LogicBio and is Chairman of the board of directors of Mereo Biopharma and of X4 Biologics. Mr. Wyzga previously served as a member of the boards of directors of Idenix Pharmaceuticals, Inc. and Altus Pharmaceuticals, Inc., and as a member of the supervisory board of Prosensa Holding B.V. He received an M.B.A. from Providence College and a B.S. from Suffolk University.

OFFICES IN THE COMPANY: Independent director, Chairman of the Board of Directors and Audit Committee

NUMBER OF SHARES OF THE CORPORATION OWNED: 0